Thrombospondin-1 plus irinotecan: A novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 3, 2004, Pages 261-266

  Allegrini, Giacomo ^a   Goulette, Frederick A ^a   Darnowski, James W ^a   Calabresi, Paul ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Colon tumor; Irinotecan; Thombospondin 1; Xenografts

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DRUG DERIVATIVE; DRUG METABOLITE; GLYCOPROTEIN; IRINOTECAN; THROMBOSPONDIN 1;

ADVANCED CANCER; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL CULTURE; CELL DIVISION; CELL GROWTH; CELL STRAIN HT29; COLON CARCINOMA; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; ENDOTHELIUM CELL; EVALUATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INJECTION; KINETICS; MORTALITY; MOUSE; NONHUMAN; NUDE MOUSE; PATHOLOGY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR XENOGRAFT; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL DIVISION; CELLS, CULTURED; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HT29 CELLS; HUMANS; KINETICS; MICE; MICE, NUDE; THROMBOSPONDIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1442359994     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0712-y     Document Type: Article

References (46)

1. Allegrini G, Goulette FA, Darnowski JW, Calabresi P (2000) The angiogenesis inhibitor thrombospondin-1 plus irinotecan significantly inhibit tumor growth in human colon tumor bearing nude mice. Proc Am Assoc Cancer Res 41:813
2. Boehm T, Folkman J, Browder T, O'Reilly SM (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404
3. Browne PV, Mosher DF, Steimberg MH, Hebbel RP (1996) Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51:296
4. Brunetti I, Falcone A, Calabresi P, Goulette FA, Darnowski JW (1990) 5-Fluorouracil enhances azidothymidine cytotoxicity. In vitro, in vivo and biochemical studies. Cancer Res 50:4026
5. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J (1988) Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48:2083
6. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effect of multiple drugs and enzyme inhibitors. In: Weber G (ed) Advances in enzyme regulation. Pergamon Press, New York, p 27
7. Cohen AM, Minsky BD, Schilsky RL (1997) Cancer of the colon. In: DeVita VT, Hellman S, Rosemberg SA (eds) Cancer. Principles and practice of oncology, 5th edn. Lippincott-Raven, Philadelphia, p 1144
8. Darnowski JW, Sawyer RC, Stolfi RL, Martin DS, LauCam C (1985) Decreased host toxicity in vivo during chronic treatment with fluorouracil. Cancer Chemother Pharmacol 14:63
9. Darnowski JW, Davol PA, Goulette FA (1997) Human recombinant interferon alpha-2a plus 3′-azido-3′-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells. Biochem Pharmacol 53:571
10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandis K, Iveson T, Carmichael J, Alakl M, Gruia G, Award L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041
11. Elion GB, Singer S, Hitchings GH (1954) Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of chemically related antimetabolites. J Biol Chem 208:477
12. Fisher LD, van Belle G (1993) One- and two-sample inference. In: Camoise RA (ed) Biostatistics, a methodology for the health sciences. Wiley, New York, p 138
13. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4
14. Fong T, Annie T, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McManon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99
15. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bismuth H, Misset JT, Levi F (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663
16. Good DJ, Polverini PJ, Rastinejad F, Le BM, Lemons RS, Frazier WA, Bouck NP (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 87:6624
17. Grem JL (1997) Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. Semin Oncol 24:S18
18. Guo N, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735
19. Herbst RS, Takeuchi H, Teicher BA (1998) Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41:497
20. Hsiang YH, Liu FL (1988) Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722
21. Iruela-Arispe M, Bornestein P, Sage H (1991) Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci U S A 88:5026
22. Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39
23. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun K, Folkman J, Hanahan ND (1991) Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095
24. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S (1996) Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77:1736
25. Lahav J (1988) Thrombospondin-1 inhibits adhesion of endothelial cells. Exp Cell Res 177:199
26. Larkin M (1999) Low-dose thalidomide seems to be effective in multiple myeloma. Lancet 354:925
27. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF (1996) Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 23:11
28. Liu B, Liao J, Rao X, Kushner S, Chung CD, Chang DD, Shuai K (1998) Inhibition of Stat-mediated gene activation of PIAS 1. Proc Natl Acad Sci U S A 95:10626
29. Nanus DM, Schimitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, CordonCardo C, Albino AP, Reuter VE (1993) Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 85:1597
30. Narazaki M, Fujimoto M, Matzumoto T, Monta Y, Saito H, Kajita T, Yoshizaki K, Naka T, Kishimoto T (1998) Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin-6 signaling. Proc Natl Acad Sci U S A 95:13130
31. Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, Joseph RR, Tuszynski P (1994) Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 73:2853
32. Nicholson SE, Hilton DJ (1998) The SOCS proteins: a new family of negative regulators of signal transduction. J Leukoc Biol 63:665
33. Offodile R, Walton T, Lee M, Stiles A, Nguyen M (1999) Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. Tumori 85:51
34. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WL, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315
35. Pantazis P, Kolielski A, Rodriquez R, Petry E, Wani M, Wall M, Giovanella BC (1994) Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts. Melanoma Res 4:5
36. Pommier Y (1996) Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol 23:3
37. Roberts DD (1996) Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 10:1183
38. Rosemurgy A, Harris J, Langleben A, Casper E, GoodeS, Rasmussen H (1999) Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol 22:247
39. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905
40. Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, Lawler J, Detmar M (1999) Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155:441
41. The American Cancer Society (2002) Colorectal cancer and early detection. Cancer Facts and Figures 2002. American Cancer Society, Atlanta
42. Tosi P, Calabresi P, Goulette F, Renaud C, Darnowski JW (1992) 3′-Azido-3′-deoxythymidine antineoplastic activity is enhanced by methotrexate in vitro and in vivo. Cancer Res 52:4069
43. Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ (1987) Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 47:4130
44. Tuszynski GP, Smith M, Rothman L, Capuzzi DM, Joseph RR, Katz J, Besa EC, Treat J, Switalska HI (1992) Thrombospondin levels in patients with malignancy. Thromb Haemost 67:607
45. Vanhoefer U, Harstrick A, Kohne CH, Achterrath W, Rustum YM, Seeber S, Wilke H (1999) Phase I study of a weekly schedule of irinotecan: high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907
46. Volpert ON, Lawler J, Bouck NP (1998) A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A 95:6343